2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Integrated Insights, Clinical Connections: Migraines
Leverage Integrated Data to Inform Better Benefit Decisions Migraines are more than just headaches, they’re a significant health challenge affecting millions of Americans,…
Read Post
CGT Space Faces Some Challenges, but There ‘Still Is a Place’ for Therapies
Reprinted with AIS Health permission from the March 2025 issue of Radar on Specialty Pharmacy. The cell and gene therapy (CGT) space…
Read Post
Navigating Medicare’s Complexities: Profitability Strategies for Pharmacy Leaders
Amid evolving Medicare regulations and market dynamics, payer leaders face unprecedented challenges in maintaining profitability while delivering quality care. Join our team of Medicare…
Read Post
Implementing a Modular PBA Model As Your Pharmacy Benefits Strategy
Transforming pharmacy benefit strategy into execution for Modular PBA models In today’s prescription drug landscape, where costs continue to soar and patients struggle to…
Read Post
2025 Drugs to Watch: A Helpful Guide for Payers
Stay Ahead of 2025 Drug Trends Managing drug trend and spend continues to be a significant challenge for payers, with specialty drug trends rising…
Read Post
Exploring The 2025 Obesity Drug Pipeline
A Snippet From The 2025 Payer’s Guide to GLP-1 Drugs In recent years, GLP-1 drugs have become increasingly popular for their effectiveness in managing…
Read Post
4 Strategies to Avoid Pitfalls in Your 2025 Project Management Initiatives
In an increasingly demanding and ever-changing healthcare environment, project management missteps can derail even the most promising initiatives. Join our industry experts as they…
Read Post
End-to-End Benefit Validation Tools Ensure Seamless Member Transitions
When a health plan changed PBMs for the first time in 10 years, PSG helped ensure a seamless implementation and transition. 1M testing claims…
Read Post
The Payer’s 2025 Guide to GLP-1 Drugs
Manage Pharmacy Benefits for GLP-1 Drugs GLP-1 drugs are a hot topic not only in pharmacy but in U.S. culture and business. Forecasts have…
Read Post
Pharmacy Benefits Research: Illuminating the Path Forward
Advancing Industry Understanding with Research For over three decades, PSG has been the expert voice in all aspects of managing pharmacy benefits. Our comprehensive…
Read Post
Stelara Biosimilars: Preparing for the Upcoming Market Shift
Leveraging Stelara Biosimilars Could be a Valuable Savings Strategy in 2025 Since its introduction in 2009, Stelara (sold by Janssen) has emerged as a…
Read Post